Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Pediatric investigation plan vs. disease epidemiology arrived with a competitor label that just got a narrower indication for labeling negotiator. That is a Pharma & Life Sciences Pharmacovigilance decision on to drop a secondary in a company with a CMC site change mid-review.

DECISION Labeling negotiator in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using pediatric investigation plan vs. disease epidemiology after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. A competitor label that just got a narrower indication is noise around an already-controlled Pharmacovigilance process in a company with a CMC site change mid-review, given pediatric investigation plan vs. disease epidemiology. 2. A competitor label that just got a narrower indication is the event in pediatric investigation plan vs. disease epidemiology that forces Proceed under protocol for labeling negotiator under Pharma & Life Sciences. 3. Pediatric investigation plan vs. disease epidemiology shows a one-file miss after a competitor label that just got a narrower indication, not a Pharmacovigilance program failure. 4. Pediatric investigation plan vs. disease epidemiology cannot decide to drop a secondary yet after a competitor label that just got a narrower indication; hold is the only Pharma & Life Sciences close a company with a CMC site change mid-review can defend.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether pediatric investigation plan vs. disease epidemiology supports the labeled claim labeling negotiator would keep. 3. Map FDA-response timing and owner in a company with a CMC site change mid-review. 4. For this Pharma & Life Sciences Pharmacovigilance file, read pediatric investigation plan vs. disease epidemiology against a competitor label that just got a narrower indication and write the one fact that would move to drop a secondary for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (pediatric investigation plan vs. disease epidemiology after a competitor label that just got a narrower indication). The follow-on Pharmacovigilance action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in pediatric investigation plan vs. disease epidemiology, then the action for labeling negotiator - Hypothesis scorecard against pediatric investigation plan vs. disease epidemiology: supported / rejected / untestable - Pharmacovigilance finding in pediatric investigation plan vs. disease epidemiology that a second reviewer can re-perform - Missing page in pediatric investigation plan vs. disease epidemiology after a competitor label that just got a narrower indication, if any